D-685, a prodrug of D-520, demonstrates enhanced anti-Parkinsonian efficacy in a reserpinized Parkinson's disease (PD) animal model compared to its parent compound D-520. It effectively reduces the buildup of human α-synuclein (α-syn) protein and readily penetrates the brain [1].

D-685（12 mg/kg；每日腹腔注射；持续1个月）能够降低α-Syn tg小鼠脑内α-突触核蛋白的累积[1]。相较于单独使用利血平，D-685（10 μmol/kg；腹腔注射）在逆转Sprague-Dawley大鼠（雄性和雌性，体重220-225 g）的运动障碍方面表现出显著效果，并在6小时的研究周期内显著提升了动作能力[1]。此外，D-685经腹腔给药后易于穿透大脑屏障，表现出一个较高的脑血浆比值（B/P: 4）[1]。